Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
J Cardiothorac Surg. 2023 Oct 4;18(1):269. doi: 10.1186/s13019-023-02368-1.
Post-implant right heart failure (RHF) has been recognized as a crucial prognostic factor in patients receiving left ventricular assist devices (LVADs), and its management has long attracted attention from cardiologists and surgeons.
This report described an 18-year-old female with acutely deteriorating heart failure due to dilated cardiomyopathy who underwent paracorporeal pulsatile-flow LVAD and developed early post-implant RHF. At postoperative day (POD) six, she was almost asymptomatic at rest on 2.5 mg/kg/min of dobutamine; however, the echocardiogram, performed as part of the daily postoperative care, revealed a severely enlarged right ventricle with a decompressed left ventricle, implying the development of post-implant RHF. Bolus infusion of saline and reduction of pump flow (6.0 L/min to 3.0 L/min) led to normalization of both ventricular shapes in 30 s, suggesting that RHF could be managed without surgical interventions. Milrinone was started on POD six, followed by sildenafil administration on POD seven. Fluid balance was strictly adjusted under the close observation of daily echocardiograms. Milrinone and dobutamine were discontinued on PODs 18 and 21, respectively. The patient was listed for a heart transplant on POD 40. Despite reduced right ventricular function (right ventricular stroke work index of 182.34 mmHg*ml/m, body surface area 1.5 m), she was successfully converted to implantable LVAD on POD 44 with no recurrence of post-implant RHF thereafter for four years.
In post-implant RHF management, early detection, together with proper and prompt medical management, is crucial to avoiding any surgical intervention. Close observation of daily echocardiograms might be helpful in detecting subclinical RHF and is useful for post-implant medical management.
植入后右心衰竭(RHF)已被认为是接受左心室辅助装置(LVAD)治疗的患者的一个重要预后因素,其管理长期以来一直受到心脏病专家和外科医生的关注。
本报告描述了一例 18 岁女性,因扩张型心肌病导致急性心力衰竭恶化,接受了体外搏动流 LVAD 治疗,并在植入后早期发生 RHF。术后第 6 天,她在多巴酚丁胺 2.5mg/kg/min 的情况下几乎无症状地休息,但作为日常术后护理的一部分进行的超声心动图检查显示右心室严重扩大,左心室减压,提示发生了植入后 RHF。盐水推注和降低泵流量(从 6.0L/min 降至 3.0L/min)在 30 秒内使两个心室的形状恢复正常,表明无需手术干预即可治疗 RHF。术后第 6 天开始使用米力农,术后第 7 天开始使用西地那非。在密切观察每日超声心动图的情况下,严格调整液体平衡。术后第 18 天和第 21 天分别停用米力农和多巴酚丁胺。该患者在术后第 40 天被列入心脏移植名单。尽管右心室功能(右心室每搏功指数 182.34mmHg*ml/m,体表面积 1.5m)降低,但她在术后第 44 天成功地转换为可植入的 LVAD,此后四年内未再发生植入后 RHF。
在植入后 RHF 的管理中,早期发现并进行适当和及时的医学治疗至关重要,可避免任何手术干预。密切观察每日超声心动图可能有助于发现亚临床 RHF,并有助于植入后的医学管理。